ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 22

Monoclonal Anti-Citrullinated Protein Antibodies Generated from RA-Derived B Cells Recognize Amino Acid Motifs Rather Than Specific Proteins

Johanna Steen1, Philip J. Titcombe2, Bjorn Forsström3, Caroline Grönwall4, Anca I. Catrina5, Daniel Lightwood6, Peter Nilsson7, Lars Klareskog1 and Vivianne Malmström1, 1Rheumatology Unit, Dept. of Medicine, Karolinska Institutet, Stockholm, Sweden, 2The Center for Immunology, Dept. of Medicine, University of Minnesota Medical School, Minneapolis, MN, 3SciLifeLab, Royal Technology Highschool,, Stockholm, Sweden, 4Dep. of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, 5Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 6Antibody-discovery, UCB-Celltech, Slough, United Kingdom, 7Affinity Proteomics, SciLifeLab, School of Biotechnology, KTH - Royal Institute of Technology, Stockholm, Sweden, Stockholm, Sweden

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: ACPA, autoimmunity and immunoglobulin (IG)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: B Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Rheumatoid arthritis (RA) associated anti-citrullinated protein autoantibodies (ACPA) develop before RA diagnosis, at which point a wide range of citrullinated proteins have been shown to be targeted based on different peptide assays. Intriguingly, ACPAs have been found to be multi-reactive even on monoclonal level. We set out to study the breadth of that multireactivity and try to determine what the antibodies recognize, as recent findings suggest that certain, but not all, ACPA may have pathogenic properties.

Methods:

We screened 6 different monoclonal ACPAs, originating from 3 different patients, 4 were derived from synovial fluid plasma cells and 2 were derived from peptide-tetramer captured B cells from peripheral blood. All ACPA mAbs have confirmed anti-CCP2 reactivity and have demonstrated multi-citrulline-peptide reactivity by ELISA. A custom-made peptide array (NimbleGen, Roche) was designed with 16aa peptides derived from 1610 extracellular matrix- or RA associated- proteins. Peptides containing either an arginine or lysine were synthesized in pairs with a modified version containing either a citrulline or a homocitrulline in the respective position. Altogether >53,000 citrullinated peptides, >49,000 carbamylated peptides and >70,000 native peptides were included. Monoclonal antibodies were run on the array at a concentration of 1ug/ml, while serum and synovial fluid were diluted 1/100.

Results:

The monoclonal ACPAs consistently displayed low reactivity (<0.06%) to unmodified peptides, while all 6 reacted to 1,000s (3.4-9.4%) of the citrullinated peptides. Intriguingly, 3 out of the 6 ACPAs also reacted with the carbamylated peptides to a similar broad extent (2.2-4.5% of the peptides). Based on the sequences from the positive peptides we could create LOGOs of the preferred amino acids. Intriguingly, two dominating aa-patterns were identified and only minor contributions from the flanking sequences were observed.

Serum and synovial fluid (SF) from the same patient as the synovial plasma cell-derived ACPAs were also assessed at both the time point of the cell draw and a 10-year follow-up. The SF samples displayed a robust citrulline-reactivity with only 10% divergence between the two samples taken 10 years apart. In contrast, the homocitrulline reactivity was significantly altered between the two time points as approximately 50% of the signals were lost at follow-up in both SF and peripheral blood.

Conclusion:

An ACPA serum response is a hallmark of seropositive RA and develops early, often before clinical symptoms. Our study of monoclonal ACPAs generated from established RA implicates that a truly broad citrulline-reactivity is found also on individual immunoglobulin level and may be the result of multiple antigen encounters which have selected for very focused citrulline-recognition with only modest contribution from flanking amino acids. This citrulline autoimmunity appears robust with minimal changes over time, while that was less true for the homocitrulline response.


Disclosure: J. Steen, None; P. J. Titcombe, None; B. Forsström, None; C. Grönwall, None; A. I. Catrina, Glaxo Smith Kline PLC, 2; D. Lightwood, Daniel Lightwood, 3; P. Nilsson, None; L. Klareskog, None; V. Malmström, None.

To cite this abstract in AMA style:

Steen J, Titcombe PJ, Forsström B, Grönwall C, Catrina AI, Lightwood D, Nilsson P, Klareskog L, Malmström V. Monoclonal Anti-Citrullinated Protein Antibodies Generated from RA-Derived B Cells Recognize Amino Acid Motifs Rather Than Specific Proteins [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/monoclonal-anti-citrullinated-protein-antibodies-generated-from-ra-derived-b-cells-recognize-amino-acid-motifs-rather-than-specific-proteins/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/monoclonal-anti-citrullinated-protein-antibodies-generated-from-ra-derived-b-cells-recognize-amino-acid-motifs-rather-than-specific-proteins/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology